Proteasome inhibition is a validated therapeutic strategy against several forms of cancer. Indeed, FDA approved proteasome inhibitors, bortezomib (BTZ), ixazomib (IXA), and carfilzomib (CAR) have had clinical success in hematological cancers such as multiple myeloma (MM) and mantle cell lymphoma. These proteasome inhibitors effectively target the constitutive proteasome. More recently, the immunoproteasome has become the target of next-generation proteasome inhibitors particularly in autoimmune disorders and inflammatory diseases.
Professor Michael Pirrung from the University of California, Riverside has developed immunoproteasome inhibitors that may be used to develop new therapies to treat a variety of diseases like cancer, autoimmune disorders and inflammatory diseases. These inhibitors are from a novel family of compounds called thiasyrbactins. This technology is advantageous because it can potentially lead to novel and effective treatments for a wide variety of conditions including cancer, Huntington’s disease, Alzheimer’s disease, macular degeneration, inflammatory bowel disease, and rheumatoid arthritis.
|United States Of America||Issued Patent||10,584,105||03/10/2020||2016-667|